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A functional adaptive immune system depends on a diverse and self-tolerant population of T 
lymphocytes that are generated in the thymus and maintained in the peripheral lymphoid organs. 
Recent studies have defined the cytokine transforming growth factor-β (TGF-β) as a critical regulator 
of thymic T cell development as well as a crucial player in peripheral T cell homeostasis, tolerance 
to self antigens, and T cell differentiation during the immune response. The unique mechanism of 
TGF-β activation and the plasticity of TGF-β signaling create a stage for TGF-β to integrate signals 
from multiple cell types and environmental cues to regulate T cells.Introduction
The defining feature of a functional immune system is the 
ability to correctly discern foreign pathogenic antigens from 
self- or other innocuous antigens and to mount an effective 
immune response. T lymphocytes are the key components 
of the cellular arm of the adaptive immune system. Elucida-
tion of the mechanisms underlying T cell regulation during 
the immune system steady state and pathogen invasion is 
fundamental to the understanding of immune system func-
tion. Studies of T cell regulation have begun to shed light on 
the pervasive and essential role that the regulatory cytokine 
transforming growth factor-β (TGF-β) plays in T cell develop-
ment, homeostasis, tolerance, and the immune response, 
thereby providing a means to grasp the underlying prin-
ciples of T cell biology. This review will discuss recent prog-
ress in understanding the regulation of T cells by TGF-β.
T lymphocytes express T cell receptors (TCRs) that recog-
nize antigens in association with molecules of the major his-
tocompatibility complex (MHC) (Box 1). The stochastic pro-
cess by which a pool of TCRs with different antigen-binding 
specificities is generated creates the inherent problem that 
some receptors have a high affinity for self-antigens or for 
innocuous environmental antigens such as those from com-
mensal organisms. Thus, to ensure immune system homeo-
stasis and to prevent an autoimmune response provoked by 
T cell recognition of self-antigens, T cells are subjected to 
selection in the thymus before they migrate to the periph-
eral lymphoid organs. T cells bearing TCRs with low affinity 
for MHC–self-antigen complexes are favored in this thymic 
selection, whereas T cells expressing TCRs with high affin-
ity for MHC–self-antigen are eliminated through apoptosis 
(Starr et al., 2003). This purge of high-affinity T cell clones 
from the T cell repertoire is not an infallible process. As a 
consequence of incomplete presentation of self-antigens in 
the thymus and the plasticity of TCR recognition of antigens, 
autoreactive T cells are present in the peripheral lymphoid 
organs of healthy individuals (Danke et al., 2004). Therefore, 
other regulatory mechanisms in addition to thymic selection 392 Cell 134, August 8, 2008 ©2008 Elsevier Inc.must hold these autoreactive T cells in check and keep them 
from triggering autoimmune disease. Once low-affinity T cell 
clones have undergone the maturation process in the thy-
mus, they relocate to the peripheral lymphoid organs, where 
they are maintained as a nonproliferating, diverse popula-
tion of naive T cells with a half-life of at least 6 months in 
mice (Jameson, 2005). Should infection occur, naive T cells 
that recognize foreign antigens derived from the invading 
pathogen are preferentially activated and then differentiate 
into effector T cells (CD4+ helper T cells or CD8+ cytotoxic T 
cells) to combat the invading pathogen. These crucial pro-
cesses of T cell development, tolerance, homeostasis, and 
differentiation are highly dependent on a regulatory network 
that is modulated by TGF-β.
Box 1. Abbreviations
CIA: collagen-induced arthritis 
CTL: cytotoxic T lymphocyte 
DC: dendritic cell 
DNRII: dominant-negative mutant of TGF-βRII 
EAE: experimental autoimmune encephalomyelitis 
ECM: extracellular matrix 
eTh17: effector Th17 
GALT: gut-associated lymphoid tissue 
IL: interleukin 
iTreg: induced CD4+Foxp3+ regulatory T 
LAP: latency-associated protein 
LTBP: latent TGF-β-binding protein 
MHC: major histocompatibility complex 
NKT: natural killer T 
nTreg: natural CD4+Foxp3+ regulatory T 
RA: retinoic acid 
RAG: recombination activating gene 
rTh17: regulatory Th17 
TA: TGF-β activator 
TCR: T cell receptor 
TF: transcription factor 
TGF-β: transforming growth factor-β 
TGF-βRI: TGF-β type I receptor 
TGF-βRII: TGF-β type II receptor 
Th: helper T lymphocyte
TGF-β belongs to a family of regulatory cytokines that have 
pleiotropic functions in a broad range of cell lineages involved 
in numerous physiological and pathological processes such 
as embryogenesis, carcinogenesis, and the immune response 
(Blobe et al., 2000). In mammals, three members of the TGF-β 
family (TGF-β1, TGF-β2, and TGF-β3) have been identified, with 
TGF-β1 being the predominant form expressed in the immune 
system (Li et al., 2006b). TGF-β is synthesized as a precursor: 
the pre region contains a signal peptide, and pro-TGF-β is pro-
cessed in the Golgi by a furin-like peptidase that removes the 
N terminus of the immature protein. A homodimer of this new 
protein, called the latency-associated protein (LAP), is nonco-
valently associated with a homodimer of mature TGF-β (Figure 
1). This latent complex can be secreted, or may associate with 
latent-TGF-β-binding protein (LTBP), which plays an important 
role in targeting TGF-β to the extracellular matrix. TGF-β can-
not bind to its receptors in its latent form—it needs to be liber-
ated from the constraints of LAP and LTBP by a TGF-β activa-
tor (TA) through LAP proteolysis or a conformational change 
(Annes et al., 2003) (Figure 1). Notably, the cells that produce 
TA can be different from those that secrete TGF-β. This unique 
activation step for TGF-β provides a means for this secreted 
molecule to integrate signals from multiple cell types to regu-
late cellular responses.
Active TGF-β mediates its biological functions by binding to 
TGF-β type I (TGF-βRI) and type II (TGF-βRII) receptors, both 
of which are serine/threonine kinases. TGF-β engagement with 
a tetrameric receptor complex consisting of two TGF-βRI mol-
ecules and two TGF-βRII molecules activates these receptor 
kinases, allowing them to phosphorylate downstream targets 
and to activate different signaling pathways (Figure 1). The sig-
naling output of TGF-β elicits diverse cellular responses that 
are primarily mediated through the actions of Smad transcrip-
tion factors (Massague and Gomis, 2006; Shi and Massague, 
2003). Active Smad protein complexes bind to DNA weakly; 
high-affinity DNA binding is achieved by the association of 
Smad proteins with a large number of transcription factor part-
ners (Massague and Gomis, 2006). In addition, TGF-β activates 
various cell type-specific Smad-independent signaling path-
ways, including those mediated by mitogen-activated protein 
kinase (MAPK), PI3K kinase, PP2A phosphatase, Rho family 
proteins, and the epithelial polarity protein Par6 (Derynck and 
Zhang, 2003; Ozdamar et al., 2005). The plasticity of Smad 
proteins in transcriptional regulation and the diversity of Smad-
independent pathways enable TGF-β to exert its pleiotropic 
actions.
TGF-β Regulates T Cell Development
Thymic T precursor cells undergo a series of molecular and 
phenotypic changes before they differentiate into mature T 
cells. One critical event in T cell differentiation occurs at the 
stage when immature T cells expressing both CD4 and CD8 
cell surface markers (CD4+CD8+) as well as αβ TCRs are sub-
jected to selection and lineage diversification.
CD8+ T Cell Differentiation
TGF-β may play a role at the CD4+CD8+ stage in T cell devel-
opment to promote thymic CD8+ T cell differentiation, but this 
remains unresolved. The initial implication of TGF-β in this process came from a study that found a 2-fold reduction in 
conventional mature CD8+ T cells (CD8+TCRhigh) in mice lacking 
the Tgfbr2 gene in CD4+CD8+ T cells (Li et al., 2006a). How-
ever, a related study using the same mouse model system 
(Marie et al., 2006) reported normal thymic CD4+ and CD8+ T 
cell differentiation in these mutant mice. Another study of mice 
reconstituted with TGF-βRII-deficient bone marrow cells dem-
onstrated the opposite effect, that is, increased proliferation 
of CD8+ thymocytes in the absence of TGF-β signaling with no 
effect on overall CD8+ T cell number (Leveen et al., 2005). The 
Figure 1. The TGF-β Module of Cellular Regulation
TGF-β is synthesized in an inactive form composed of a TGF-β dimer in asso-
ciation with the latency-associated protein (LAP). This latent TGF-β molecule 
can be secreted as such, or can form a complex with latent-TGF-β-binding 
protein (LTBP) that mediates its deposition to the extracellular matrix (ECM). 
TGF-β becomes activated after the engagement of a TGF-β activator (TA) that 
triggers LAP degradation or alters LAP’s conformation in response to environ-
mental cues. Active TGF-β binds to a tetrameric complex composed of TGF-β 
receptor II (TGF-βRII) and TGF-β receptor I (TGF-βRI) and initiates signaling 
pathways that are dependent on the kinase activity of the receptors. Activated 
TGF-βRI phosphorylates the transcription factors Smad2 and Smad3, trigger-
ing their translocation into the nucleus in complex with the proteins Smad4 
or TIF1γ. Smad complexes in association with additional transcription fac-
tors (TFs) bind to the regulatory sequences in target genes and regulate gene 
expression by recruiting transcription cofactors. In addition, TGF-β activates 
Smad-independent pathways such as those mediated by mitogen-activated 
protein kinase (MAPK), PI3K kinase, PP2A phosphatase, Rho family proteins, 
and the epithelial polarity protein Par6, which trigger different cell type-spe-
cific responses.Cell 134, August 8, 2008 ©2008 Elsevier Inc. 393
results of this study, however, may have been confounded by 
the fact that CD8+ thymocytes were not separated into mature 
CD8+TCRhigh T cells and immature CD8+TCRlow single positives. 
Because CD8+TCRlow single-positives cycle more actively than 
mature T cells, defects in CD8+ T cell maturation could lead 
to increased presentation of immature CD8+TCRlow single posi-
tives among CD8+ thymocytes and the hyperproliferation phe-
notype of CD8+ T cells. Furthermore, all TGF-βRII-deficient 
mice eventually developed severe inflammatory disorders. 
Although the time points chosen for the analysis of thymic phe-
notypes precede the appearance of severe immunopathology, 
systemic inflammation may affect thymic T cell development. 
Figure 2. TGF-β Regulates T Cells
The cytokine TGF-β regulates T cell development, homeostasis, tolerance, 
and immunity. TGF-β signaling in T cells promotes differentiation of thymic 
T cells into natural killer T (NKT) cells, natural regulatory T (nTreg) cells, and 
CD8+ T cells. In peripheral tissues, TGF-β signaling in T cells is likely to be es-
sential for the survival of low-affinity CD4+ and CD8+ T cells. It also modulates 
immune tolerance by inhibiting high-affinity CD4+ and CD8+ T cell proliferation 
and differentiation into T helper 1 (Th1), Th2, and cytotoxic T lymphocytes 
(CTL). In addition, TGF-β signaling in nTreg cells inhibits their proliferation 
but supports their maintenance in peripheral lymphoid organs, a process 
likely mediated by TGF-β control of nTreg cell survival. TGF-β also positively 
regulates differentiation of certain peripheral T cells in conjunction with other 
factors. TGF-β promotes the differentiation of induced Treg (iTreg) cells that 
is potentiated by the cytokine interleukin-2 (IL-2) and retinoic acid (RA). In the 
presence of IL-6, TGF-β drives the differentiation of Th17 cells and maintains 
them in a regulatory state (rTh17). Stimulation of rTh17 cells by IL-23 in the 
absence of TGF-β enables these cells to acquire effector functions and pro-
motes their differentiation into effector Th17 cells (eTh17).394 Cell 134, August 8, 2008 ©2008 Elsevier Inc.Indeed, preliminary work in a mouse strain that circumvents 
this inflammation problem again suggests a role for TGF-β sig-
naling in CD8+ T cell differentiation. These T cell-specific TGF-
βRII-deficient H-Y TCR-transgenic mice harbor H-Y CD8+ T 
cells that exclusively recognize a male mouse-specific Y chro-
mosome-associated antigen with high affinity but are positively 
selected by low-affinity self-antigens in female mice. In female 
H-Y TCR-transgenic mice where a deletion of the Rag2 gene 
(recombination activating gene 2) limits the T cell population to 
a single TCR specificity, no inflammation was observed in the 
absence of Tgfbr2 expression in T cells. In these mice, thymic 
maturation of TGF-βRII-deficient CD8+ H-Y T cells showed the 
same attenuation (M.O.L., unpublished data) as was observed 
for TGF-βRII-deficient CD8+ T cells in mice with normal poly-
clonal T cells (Li et al., 2006a). These new findings suggest that 
at least for some TCR specificities, TGF-β signaling in T cells 
promotes thymic CD8+ T cell differentiation.
nTreg and NKT Cell Differentiation
In addition to conventional CD4+ and CD8+ T lymphocytes, 
CD4+CD8+ T cells also give rise to the regulatory T cell lineages that 
include natural CD4- and Foxp3-expressing (CD4+Foxp3+) regu-
latory T (nTreg) cells and CD1d-dependent natural killer T (NKT) 
cells (Kronenberg and Rudensky, 2005). nTreg cells are essen-
tial regulators of peripheral T cell tolerance, the development of 
which is controlled by the affinity of TCRs for MHC II–self-peptide 
complexes and by costimulatory and cytokine signaling pathways 
(Liston and Rudensky, 2007). Experiments determining the func-
tion of TGF-β signaling in nTreg cell development were performed 
in the TGF-βRII T cell-specific deletion mouse models. In two 
studies, TGF-β signaling in T cells appeared to be dispensable for 
the development of nTreg cells in 12- to 16-day-old mice (Li et al., 
2006a; Marie et al., 2006). However, a recent report suggests an 
earlier requirement for TGF-β signaling (Liu et al., 2008). Using a 
conditional deletion of the Tgfr1 gene in T cells, Liu et al. showed 
that this loss of TGF-βRI blocked nTreg cell differentiation in 3- to 
5-day-old mice but triggered nTreg cell expansion in mice older 
than 1 week (Liu et al., 2008). The later expansion, a phenomenon 
also observed in mice deficient in TGF-βRII (Li et al., 2006a), was 
associated with enhanced nTreg cell proliferation in response to 
the cytokine interleukin-2 (IL-2). Indeed, genetic ablation of IL-2 in 
TGF-βRI-deficient mice resulted in a diminished number of thy-
mic nTreg cells (Liu et al., 2008). These findings reveal opposing 
functions for TGF-β signaling in nTreg cell development that are 
dependent on mouse age, although the molecular mechanism by 
which TGF-β promotes early nTreg cell differentiation remains to 
be determined.
The development of NKT cells is dependent on the presenta-
tion of MHC I-like CD1d-self-glycolipid antigens by CD4+CD8+ 
T cells; NKT cells express TCRs that recognize glycolipid anti-
gens in association with the CD1d molecule (Bendelac et al., 
1997). In contrast to the early developmental defect seen in 
nTreg cell differentiation in the absence of TGF-β signaling, thy-
mic and peripheral NKT cell numbers were sharply reduced in 
T cell-specific TGF-βRII-deficient mice analyzed at all ages (Li 
et al., 2006a; Marie et al., 2006). Taken together, these recent 
studies have uncovered positive regulatory roles for TGF-β sig-
naling in the development of multiple T cell lineages (Figure 2). 
T cell development in general is controlled by the TCR, costim-
ulatory receptor, and cytokine (e.g., common-γ chain cytokine) 
signaling pathways. How TGF-β signaling crosstalk with these 
pathways regulates CD8+ T cell, nTreg cell, and NKT cell differ-
entiation will be an interesting topic for future investigation.
TGF-β Regulates Naive T Cell Homeostasis
T cells are maintained at a constant number in adult animals 
under steady-state conditions, even after thymic atropy that 
results in diminished T cell production (Jameson, 2005). This 
maintenance of a diverse and long-lived naive T cell repertoire 
is fundamental to the function of the adaptive immune system 
because these T cells will be called upon to defend the host 
when infection occurs. Naive T cell homeostasis is regulated 
by cytokine signaling pathways such as that of IL-7 and also 
possibly by the engagement of MHC–self-antigen complexes 
in peripheral tissues (Surh and Sprent, 2005). TGF-β signal-
ing in T cells is essential for the maintenance of peripheral T 
cell tolerance (see below), and T cells from TGF-β1-deficient 
mice or mice with T cell-specific inactivation of TGF-β recep-
tors exhibit hyperactivation of their T cell populations. The loss 
of naive T cells in these mice could be caused by a lack of thy-
mic production of naive T cells, activation and differentiation of 
naive T cells by low-affinity MHC–self-antigen complexes, the 
ability of activated T cells to out-compete naive T cells, com-
promised survival or migration of naive T cells to peripheral 
lymphoid organs, or a combination of these possibilities.
Recent studies with TCR-transgenic mouse models have 
begun to address how TCR specificity modulates T cell 
responses under conditions of compromised TGF-β regu-
lation and to decipher the reason for naive T cell loss when 
TGF-β signaling is disrupted (Bommireddy et al., 2006; Li et 
al., 2006a; Marie et al., 2006; Robinson et al., 2006). In one of 
these studies, the effects of defective TGF-β signaling in T cells 
was examined in mice engineered such that T cell TCRs had a 
high binding affinity only for a nonself–MHC II antigen (OT-II T 
cells). This enabled the complicating factors of T cell compe-
tition and host systemic inflammation to be circumvented (Li 
et al., 2006a). In these mice, ablation of the Tgfbr2 gene in T 
cells did not affect T cell selection, suggesting that thymic pro-
duction under these conditions was unaffected by the lack of 
TGF-β signaling. In contrast to the hyperactivated phenotype 
of TGF-βRII-deficient CD4+ T cells in mice harboring a normal 
polyclonal T cell population with mixed TCR affinities, most 
peripheral TGF-βRII-deficient OT-II T cells maintained a naive 
T cell phenotype and did not differentiate into T helper 1 (Th1) 
or Th2 effector T cells (Li et al., 2006a). Similar observations 
were also made with TGF-βRII-deficient T cells or T cells from 
TGF-β1-deficient mice with other single nonself TCR affinities 
(TEα transgenic T cells and DO11.10 T cells) (Bommireddy et 
al., 2006; Marie et al., 2006; Robinson et al., 2006). These find-
ings suggest that the loss of naive CD4+ T cells observed when 
TGF-β signaling is lacking is not likely due to activation and 
differentiation of naive T cells. Instead, a striking observation 
suggests another explanation. TGF-βRII-deficient OT-II T cells 
were seen to undergo a high rate of cell death and were largely 
depleted in the peripheral lymphoid organs (Li et al., 2006a). 
These findings demonstrate an essential role for TGF-β signal-
ing in promoting naive OT-II T cell survival and also imply that cell death at least partly accounts for the loss of CD4+ naive T 
cells in T cell-specific TGF-βRII-deficient mice. This conclusion 
is supported by a recent study that determined the TCR diver-
sity of CD4+ T cells in TGF-β1-deficient mice (Robinson and 
Gorham, 2007). Peripheral but not thymic TGF-β1-deficient 
CD4+ T cells exhibited a nonpolyclonal distribution of the third 
complementarity-determining region of TCR Vβ chains, which 
could be explained by the depletion of peripheral naive CD4+ 
T cells in these mice. Future studies with additional TCR trans-
genic models are needed to corroborate these findings. Poten-
tial crosstalk between the TGF-β pathway and other signaling 
pathways involved in naive T cell homeostasis also warrants 
investigation. The role of TGF-β signaling in regulating naive 
CD8+ T cells also remains to be determined. Preliminary results 
from the study of peripheral T cells in the aforementioned H-Y 
TCR-transgenic mouse strain showed that the lack of TGF-β 
signaling in CD8+ H-Y T cells also led to diminished mature T 
cell numbers in the peripheral lymphoid organs of female mice 
(M.O.L., unpublished data). These findings suggest that TGF-β 
may have an essential role in promoting the survival of both 
CD4+ and CD8+ naive T cells that interact with low affinity to 
self-antigens (Figure 2) to maintain a diverse repertoire of T 
cells.
TGF-β Regulates Peripheral T Cell Tolerance
Multiple mechanisms have evolved to control T cell-mediated 
autoimmunity. These include the deletion of high-affinity self-
reactive T cell clones in the thymus (Mathis and Benoist, 2004) 
and various peripheral mechanisms that keep escaped auto-
reactive T cells in check (Walker and Abbas, 2002). Active 
immune suppression by cytokine TGF-β1 or CD4+Foxp3+ Treg 
cells is a pivotal mechanism of peripheral T cell tolerance (Li et 
al., 2006b; Sakaguchi et al., 2008). Indeed, mice lacking either 
TGF-β1 or Foxp3, the transcription factor required for Treg cell 
function, develop early fatal multifocal inflammatory diseases.
T Cells as a Direct TGF-β Target
The inflammatory disorder developed in TGF-β1-deficient mice 
is characterized by the hyperactivation of T cells and the pro-
gressive infiltration of leukocytes into multiple organs (Kulkarni 
et al., 1993; Shull et al., 1992). Depletion of either CD4+ or CD8+ 
T cells alleviates this immunopathology (Kobayashi et al., 1999; 
Letterio et al., 1996), thereby demonstrating that T cells are 
essential mediators of the disease. Because disease develop-
ment is not prevented by the absence of foreign antigens when 
TGF-β1-deficient mice are raised under germ-free conditions 
(Boivin et al., 1997), the T cell activation observed seemed 
likely to be driven by self-antigens. However, because TGF-β1 
can modulate the activity of multiple leukocyte lineages, it was 
not clear from these studies whether TGF-β1 directly con-
trolled T cell tolerance. In early 2000, work by several groups, 
using transgenic approaches to inhibit TGF-β signaling in T 
cells, demonstrated a specific disturbance of T cell homeosta-
sis or tolerance in the absence of TGF-β signaling (Gorelik and 
Flavell, 2000; Lucas et al., 2000). In one study, the expression 
of a dominant-negative mutant of TGF-βRII (DNRII) from the 
CD4 promoter that lacks the CD8 silencer inhibited TGF-β sig-
naling in CD4+ and CD8+ T cells, leading to the activation and 
differentiation of CD4+ and CD8+ T cells and the development Cell 134, August 8, 2008 ©2008 Elsevier Inc. 395
of inflammatory disease (Gorelik and Flavell, 2000). In another 
report, expression of DNRII from the CD2 promoter resulted 
in a CD8+ T cell lymphoproliferative disorder with little inflam-
mation (Lucas et al., 2000). Later studies demonstrating that T 
cell-specific TGF-βRII- or TGF-βRI-deficient mice developed a 
neonatal lethal inflammatory disease similar to that of TGFβ1-
deficient mice (Li et al., 2006a; Liu et al., 2008; Marie et al., 
2006) further corroborate the earlier findings and establish T 
cells as the central direct target of TGF-β1-regulated immune 
tolerance in vivo.
TGF-β Control of Effector T Cells and nTregs
So what is the mechanism underlying TGF-β regulation of 
T cell tolerance? In peripheral T cell tolerance, extrathy-
mic immune regulation by Treg cells plays an essential role. 
Indeed, as mentioned above, mice devoid of the Treg cell-
specific transcription factor Foxp3 develop a similarly severe 
autoimmune phenotype as T cell-specific TGF-βRII-deficient 
mice (Brunkow et al., 2001; Fontenot et al., 2003). Intriguingly, 
it has been observed that despite uncompromised thymic 
production of nTreg cells in 12- to 16-day-old T cell-specific 
TGF-β receptor-deficient mice, Treg cell number is reduced 
in the spleens of these mice (Li et al., 2006a; Liu et al., 2008; 
Marie et al., 2006). These findings are consistent with simi-
lar observations in TGF-β1-deficient mice (Marie et al., 2005), 
suggesting that a loss in TGF-β signaling somehow affects 
Treg cells. Because TGF-βRII-deficient Treg cells proliferate 
at a higher rate than wild-type Treg cells (Li et al., 2006a), the 
compromised maintenance of Treg cells is likely due to their 
failed survival. The observation that neonatal thymectomy of 
mice on day 3 substantially diminishes peripheral Treg cells 
(Sakaguchi et al., 2008), taken in the context of the finding 
that thymic Treg cell differentiation is kinetically slower than 
that of nonregulatory CD4+ T cells (Fontenot et al., 2005), sug-
gests that thymus-derived nTreg cells make up the majority, 
if not all, of the peripheral Treg cells in young mice. Together, 
these studies suggest that the failed maintenance of nTreg 
cells likely accounts for most of the Treg cell reduction in mice 
lacking TGF-β signaling. But is the reduced Treg cell number 
the cause of cell tolerance loss in TGF-βRII-deficient mice? Or 
is a lack of cell-intrinsic control of T cell activation by TGF-β a 
contributing factor? Alternatively, is this failed maintenance of 
TGF-βRII-deficient Treg cells a direct consequence of a lack 
of TGF-β signaling in nTreg cells or of environmental factors 
such as severe systemic inflammation?
These questions were addressed in a series of T cell transfer 
and bone marrow chimera experiments. Although the trans-
fer of wild-type Treg cells to neonatal TGF-βRII-deficient mice 
restores Treg cell number to the level of wild-type mice, it is 
unable to correct the phenotypes of hyper-T cell activation and 
autoimmune disease development (Li et al., 2006a). Therefore, 
depletion of Treg cells does not solely account for the loss of 
T cell tolerance in TGF-βRII-deficient mice. These findings are 
consistent with earlier reports using CD4-DNRII transgenic 
T cells. In one of these studies, Treg cells were incapable of 
suppressing the inflammatory bowel disease induced by naive 
CD4-DNRII CD4+ T cells in a mouse model of colitis, a condi-
tion associated with T cell activation and differentiation (Fahlen 
et al., 2005). Intact TGF-β signaling was also required for Treg 396 Cell 134, August 8, 2008 ©2008 Elsevier Inc.cell-mediated suppression of CD8+ T cell activation in mouse 
models of diabetes and tumor immunity (Chen et al., 2005; 
Green et al., 2003; Mempel et al., 2006).
The precise functions of TGF-β signaling in the control of 
effector T cells and Treg cells have been further studied in 
mixed bone marrow chimera experiments. By creating chi-
meric mice that harbor both wild-type and TGF-βRII-deficient 
T cells, cell-intrinsic effects can be differentiated from the 
effects of cell-extrinsic environmental changes. Strikingly, 
TGF-βRII-deficient T cell populations exhibited a more acti-
vated and differentiated phenotype than wild-type T cell pop-
ulations in the chimeric mouse. Furthermore, chimeric mice 
had a lower number of TGF-βRII-deficient Treg cells relative 
to wild-type Treg cells (Li et al., 2006a; Marie et al., 2006). 
These findings demonstrate that TGF-β promotes T cell self-
tolerance through direct regulation of both effector T cells 
and nTreg cells (Figure 2).
TGF-β Control of iTreg Cells
In addition to nTreg cells that are produced in the thymus, naive 
T cells can acquire Foxp3 expression and differentiate into 
induced Treg (iTreg) cells in peripheral tissues (Bluestone and 
Abbas, 2003). In vitro activation of CD4+CD25− or CD4+Foxp3− T 
cells in the presence of TGF-β leads to their acquisition of T cell 
suppressive activity, which is associated with the induction of 
Foxp3 expression (Chen et al., 2003b; Fantini et al., 2004; Wan 
and Flavell, 2005; Zheng et al., 2002). TGF-β induction of Foxp3 
expression appears to be mediated by the recruitment of its 
downstream transcription factor Smad3 to a Foxp3 enhancer 
element (Tone et al., 2008). TGF-β-induced iTreg cell differen-
tiation was augmented by the T cell-produced cytokine IL-2 
(Davidson et al., 2007; Zheng et al., 2007), which activates the 
transcription factor STAT5 for binding to the Foxp3 promoter 
(Burchill et al., 2007). These findings suggest that Smad3 may 
synergize with STAT5 to induce Foxp3 gene transcription (Fig-
ure 3). Overexpression of TGF-β1 in the pancreatic islets also 
resulted in expansion of CD4+Foxp3+ Treg cells that protected 
nonobese diabetic (NOD) mice from developing diabetes (Peng 
et al., 2004). Taken together, these observations suggest that 
when TGF-β is present in excess, it can induce Foxp3 expres-
sion and the differentiation of iTreg cells.
Endogenous TGF-β may also be involved in the induction of 
iTreg cells in peripheral tissues. The delivery of low doses of ago-
nistic peptide ligands to steady-state dendritic cells can induce 
de novo generation of Treg cells from naive T cells (Kretschmer 
et al., 2005). The efficiency of this conversion appeared to be 
inversely correlated with the rate of cell proliferation and was 
inhibited by high-dose antigens or costimulation with a CD40 
antibody agonist. Although proliferation was detrimental to the 
induction of iTreg cells during the time window of conversion, 
converted iTreg cells maintained a stable phenotype and could 
be expanded upon immunization with antigens in the presence 
of adjuvants, nonantigenic substances that are needed to fully 
activate immune cells in the absence of an infection. Inhibi-
tion of TGF-β signaling in naive T cells by the expression of 
DNRII reduced conversion of iTreg cells in this mouse model 
that typically exhibited T cell hyperproliferation. It remains to 
be determined whether TGF-β inhibition of T cell proliferation 
provides the mechanism for its role in promoting iTreg cell dif-
Figure 3. TGF-β Engages Multiple Signaling 
Pathways to Control T Cell Development
The Smad2/3 complexes are involved in TGF-β in-
hibition of interleukin-2 (IL-2), interferon-γ (IFN-γ), 
and granzyme B transcription required for effector T 
helper 1 (Th1), Th2, and cytotoxic T lymphocyte (CTL) 
proliferation and differentiation. In addition, TGF-β 
blocks T cell receptor (TCR)-induced Tec kinase Itk 
activation and Ca2+ responses that are required for 
the expression of other transcription factors such as 
NFAT, T-bet, and GATA-3, which are also involved in 
T cell activation and differentiation. Induced regula-
tory T (iTreg) cell differentiation triggered by TGF-β 
occurs via Smad3-dependent induction of Foxp3 
expression, which is enhanced by activation of the 
transcription factor STAT5 (induced by the cytokine 
IL-2). TGF-β induction of Th17 cell differentiation is 
associated with its induction of RORγt expression, 
which is potentiated by the IL-6-activated transcrip-
tion factor STAT3. The transcription factor Foxp3 
interacts with the transcription factor RORγt and 
suppresses its function, providing a mechanism for 
the reciprocal differentiation of iTreg and Th17 cells. 
The mechanisms of TGF-β-induced development of 
natural regulatory T (nTreg) cells, natural killer T (NKT) 
cells, and CD8+ T cells are unknown. How TGF-β 
regulates the survival of low-affinity CD4+ and CD8+ 
T cells and maintains nTreg cells is also unknown.ferentiation. The contribution of iTreg cells generated via this 
pathway to the peripheral repertoire of Treg cells also remains 
to be investigated.
iTreg cells can also be generated in the gut-associated lym-
phoid tissue (GALT). In a T cell transfer mouse model, a subset of 
polyclonal CD4+Foxp3− T cells were converted to iTreg cells and 
accumulated in the GALT (Sun et al., 2007). Naive transgenic T 
cells could also differentiate into iTreg cells in response to orally 
administered antigens (Coombes et al., 2007). The preferential 
induction of iTreg cells at the mucosal site has been attributed to 
GALT dendritic cells, a major subset of which expresses the sur-
face marker protein CD103. GALT dendritic cells have the unique 
ability to imprint T cells for migration back to the gut by induc-
ing the expression on T cells of homing receptors such as the 
α4β7 integrin and cc chemokine receptor 9 (Mora et al., 2003). 
Notably, mucosal dendritic cells, especially the CD103+ subset, 
expressed high amounts of retinal dehydrogenase, the enzyme 
that converts vitamin A to its metabolite retinoic acid (RA), the 
molecule responsible for the upregulation of gut-homing recep-
tors on T cells (Iwata et al., 2004). Interestingly, administration of 
neutralizing TGF-β antibody or RA receptor inhibitors attenuated 
the generation of iTreg cells, whereas addition of RA potentiated 
TGF-β-induced iTreg cell differentiation (Benson et al., 2007; 
Coombes et al., 2007; Mucida et al., 2007; Sun et al., 2007). 
Thus, CD103+ dendritic cell-induced conversion of iTreg cells is 
dependent on both TGF-β and RA. These studies reveal a new 
pathway for the generation and homing of iTreg cells to the GALT 
(Figure 2), which may provide an important mechanism for the 
induction of tolerance to innocuous mucosal antigens such as 
those derived from commensal flora or those of dietary origins.
TGF-β Control of Effector T Cell Differentiation
Activation of naive T cells during immune responses leads to 
their differentiation into various effector T cell subsets that 
are capable of killing target cells, in the case of CD8+ T cells, 
or capable of providing helper function, in the case of CD4+ T cells. These armed effector T cells play important roles in 
host defense against pathogen invasion. When dysregulated, 
however, effector T cells can also induce the development of 
autoimmune diseases or atopic syndromes such as asthma 
and allergy. Effector T cell differentiation is orchestrated by 
signals from the TCR, costimulatory molecules, and cytokine 
signaling pathways. This combinatorial input, often imprinted 
by the nature of infectious agents, culminates in the expression 
of key transcription factors that specify the T cell phenotypes. 
For example, the expression of the transcription factor T-bet 
specifies Th1 cells, whereas the expression of GATA-3 speci-
fies Th2 cells. RORγt expression generates the newly identi-
fied Th17 cells, and a combination of T-bet and eomesodermin 
expression specifies cytotoxic T lymphocytes development.
Studies of T cell-specific TGF-βRII-deficient mice have 
revealed a cell-intrinsic role for TGF-β signaling in the preven-
tion of T cell proliferation and activation, as well as in the inhibi-
tion of effector T cell differentiation (Li et al., 2006a; Marie et al., 
2006). TGF-β inhibited the expression of the T cell mitogenic 
cytokine IL-2 in vitro in a Smad3-dependent manner (McKarns 
et al., 2004) (Figure 3). TGF-β also potently inhibited Th1 and 
Th2 cell differentiation in vitro through the downregulation of 
T-bet and GATA-3 expression, respectively (Gorelik et al., 2000, 
2002; Heath et al., 2000; Neurath et al., 2002). This inhibition 
has been associated with the TGF-β blockade of TCR-induced 
activation of the Tec kinase Itk, calcium ion influx in T cells, 
and the activation of the transcription factor NFAT (Chen et al., 
2003a) (Figure 3). Consistent with these findings, CD4+ T cells 
from CD4-DNRII mice, which have attenuated TGF-β signal-
ing, spontaneously differentiated into Th1 and Th2 cells (Gore-
lik and Flavell, 2000). Interestingly, CD4+ T cells from T cell-
specific TGF-βRII-deficient mice, which have more complete 
elimination of TGF-β signaling than those from CD4-DNRII 
mice, produced copious amounts of the cytokine interferon-γ 
(IFN-γ) and differentiated almost exclusively into Th1 cells (Li et Cell 134, August 8, 2008 ©2008 Elsevier Inc. 397
al., 2006a; Marie et al., 2006). These findings suggest that Th1 
cell differentiation likely represents a default effector pathway 
for CD4+ T cells in the absence of TGF-β signaling. However, 
it remains to be determined whether the difference of CD4+ 
effector T cell differentiation observed in CD4-DNRII mice and 
T cell-specific TGF-βRII-deficient mice is a consequence of 
varied inhibition of TGF-β signaling or is due to distinct antigen 
stimulation of CD4+ T cells.
Associated with the dominant Th1 cell differentiation phe-
notype, peripheral CD4+ T cells from T cell-specific TGF-
βRII-deficient mice expressed high amounts of T-bet (Li et 
al., 2006a; Marie et al., 2006). Reduced IFN-γ-producing Th1 
cells and increased IL-4-producing Th2 cells were observed 
in T cell-specific TGF-βRII-deficient mice also lacking T-bet 
(Li et al., 2006a), consistent with a function of T-bet in pro-
moting Th1 and suppressing Th2 cell differentiation (Finotto 
et al., 2002). Intriguingly, deficiency of T-bet also resulted in 
extensive depletion of TGF-βRII-deficient CD4+ T cells (Li et 
al., 2006a). This prosurvival function of T-bet is associated with 
T-bet regulation of CD122 expression in CD4+ T cells. CD122 
is the shared receptor β chain for cytokines IL-15 and IL-2. 
Indeed, IL-15-triggered CD122 signaling enhanced the sur-
vival of TGF-βRII-deficient CD4+ T cells (Li et al., 2006a). These 
findings, together with the observation that TGF-βRII-deficient 
naive CD4+ T cells underwent high rates of cell death, suggest 
that lack of TGF-β signaling in T cells results in cell death of 
CD4+ T cells unless they are activated and differentiate into 
T-bet-expressing Th1 cells. Therefore, the prosurvival function 
of T-bet likely accounts for the prominent Th1 cell phenotype 
observed in T cell-specific TGF-βRII-deficient mice.
In addition to limiting CD4+ T cell differentiation, TGF-β is 
also a potent inhibitor of CD8+ T cell activation and differen-
tiation (Figure 2). A subset of TGF-βRII-deficient CD8+ T cells, 
but not wild-type CD8+ T cells, expressed cell surface mark-
ers that are typically found on NK cells such as NK1.1 and 
NKG2D (Marie et al., 2006). NK1.1+ T cells induced more severe 
immunopathology than NK1.1− T cells upon adoptive-transfer 
to RAG1-deficient mice. The differentiation of NK1.1+ T cells is 
due to the activation of TGF-βRII-deficient T cells in peripheral 
tissues, because the transfer of cultured NK1.1− T cells lacking 
the Tgfbr2 gene to recipients with abnormally low blood lym-
phocyte levels (lymphopenic) allowed the cells to acquire NK 
cell markers and the ability to induce disease pathology (Marie 
et al., 2006). TGF-βRII-deficient CD8+ T cells also produced 
high amounts of IFN-γ and cytolytic molecules, including FasL, 
perforin, and granzymes (Li et al., 2006a; Marie et al., 2006). 
These finding are consistent with a study of TGF-β regula-
tion of CD8+ T cell responses in the context of tumor immu-
nity (Thomas and Massague, 2005). Neutralization of TGF-β 
by the administration of soluble TGF-βRII potentiated immune 
responses to thymic tumor cells injected into mice. This 
response was associated with the expansion of tumor-specific 
cytotoxic T lymphocytes that expressed high levels of cytolytic 
molecules (Thomas and Massague, 2005). Gene expression 
profiling experiments demonstrated that TGF-β strongly inhib-
ited expression of the cytolytic genes in CD8+ T cells. TGF-β 
inhibition of granzyme B expression was associated with the 
recruitment of its downstream transcription factors Smad2 398 Cell 134, August 8, 2008 ©2008 Elsevier Inc.and Smad3 to the Gzmb promoter where they synergize with 
CREB and ATF1 transcription factors to block transcription 
(Thomas and Massague, 2005). siRNA knockdown of Smad2 
and Smad3, but not Smad3 alone, alleviates TGF-β inhibition of 
granzyme B expression (Thomas and Massague, 2005). These 
observations suggest that Smad2 and Smad3 are redundant in 
the control of granzyme B expression (Figure 3). Future stud-
ies with mice bearing T cell-specific deletion of Smad2 and/or 
Smad3 genes can be used to test this hypothesis.
TGF-β Regulates Th17 Cells
By secreting cytokines and other effector molecules, CD4+ 
helper T cells mobilize various host cell types to tailor the 
immune response to the specific invading pathogen. It is gen-
erally thought that Th1 cells secrete IFN-γ and lymphotoxin 
to activate the cellular arm of the adaptive immune system to 
combat intracellular pathogens, whereas Th2 cells produce 
the cytokines IL-4, IL-5, and IL-13, which direct antibody pro-
duction to control extracellular parasites. Recent studies have 
expanded the Th1-Th2 cell paradigm with the addition of a 
newer helper T cell type, the Th17 cell (McGeachy and Cua, 
2008). Although the physiological role of Th17 cells remain to 
be fully explored, it is known that they secrete a distinct set 
of cytokines, including IL-17A, IL-17F, and IL-22, that act on a 
broad range of innate immune and nonhematopoietic cells to 
protect the host from a subset of extracellular pathogens.
A New Type of T Helper Cell
As with Th1 and Th2 cells, dysregulated Th17 cells can trig-
ger immunopathology. In fact, one of the original clues to the 
existence of Th17 cells came from the studies of adjuvant-
induced autoimmune diseases such as experimental allergic 
encephalomyelitis (EAE) and collagen-induced arthritis (CIA). 
These autoimmune diseases were thought to be triggered by 
dysfunctional Th1 cells whose differentiation is regulated by 
the innate immune cytokine IL-12 (Murphy and Reiner, 2002) 
until the startling finding that the cytokine IL-23 and not IL-12 
was essential for the induction of EAE or CIA (Cua et al., 2003; 
Langrish et al., 2005; Murphy et al., 2003). This seminal discov-
ery challenged the belief that Th1 cells were responsible for 
these diseases. Recent studies have further established the 
IL-17A-producing T cells as a distinct lineage of helper T cells 
whose differentiation is controlled by the transcription factor 
RORγt (Ivanov et al., 2006) but inhibited by Th1 or Th2 cytok-
ines (Harrington et al., 2005; Park et al., 2005).
Th17 Cell Differentiation
Although IL-23 is indispensable for the development of 
pathological Th17 cell responses in vivo, it does not induce 
Th17 cell differentiation from naive CD4+ T cells. In contrast 
to the inhibitory effects of TGF-β on Th1 and Th2 cell dif-
ferentiation, recent studies have established TGF-β as an 
essential regulator of Th17 cell differentiation from naive T 
cells. One of the reports found that naive T cells activated 
in the presence of Treg cells produced low amounts of 
IFN-γ but expressed high levels of IL-17A (Veldhoen et al., 
2006a). However, neutralization of TGF-β in an in vitro cul-
ture environment containing naive T cells, Treg cells, and 
lipopolysaccharide (LPS)-activated dendritic cells inhibited 
Th17 cell differentiation. Interestingly, the study also found 
that in addition to TGF-β, IL-6 produced by LPS-stimulated 
dendritic cells was also required for the differentiation of 
Th17 cells. This requirement for IL-6 in modulating TGF-β 
regulatory effects on T cell differentiation was substanti-
ated by another study showing that whereas TGF-β alone 
induced Foxp3 expression and iTreg cell differentiation from 
activated CD4+ T cells, inclusion of IL-6 in the T cell cul-
ture inhibited iTreg cell generation and diverted T cell dif-
ferentiation to the Th17 cell lineage (Bettelli et al., 2006). IL-6 
induction of Th17 cells has been attributed to its activation 
of the transcription factor STAT3 (Yang et al., 2007a) (Figure 
3). However, the molecular mechanisms of TGF-β signaling 
in Th17 cell differentiation remain to be determined. Consis-
tent with these in vitro studies, overexpression of TGF-β1 in 
T cells enhanced Th17 cell differentiation in mice (Bettelli et 
al., 2006). Concordantly, Th17 cell numbers were reduced in 
TGF-β1-deficient or CD4-DNRII mice (Mangan et al., 2006; 
Veldhoen et al., 2006b).
Although TGF-β and IL-6 are essential for the initial com-
mitment of CD4+ T cells to the Th17 cell lineage, they may 
not be sufficient to induce the pathological effector Th17 cell 
responses in vivo. In a T cell transfer model of EAE, myelin-
reactive T cells expanded by IL-23, but not those expanded 
by TGF-β plus IL-6, induced disease in mice (McGeachy et al., 
2007). Intriguingly, TGF-β- and IL-6-stimulated Th17 cells pro-
duced high amounts of IL-10 that suppressed the immunopa-
thology induced by IL-23-stimulated Th17 cells. From this, it 
appears that TGF-β and IL-6 together drive the differentiation 
of Th17 cells to a state with regulatory activity (regulatory Th17, 
rTh17) associated with IL-10 production. In contrast, contin-
ued stimulation and expansion of rTh17 cells by IL-23 in the 
absence of TGF-β leads to the acquisition of full effector Th17 
cell functions (effector Th17, eTh17; Figure 2) including the pro-
duction of pathogenic chemokines and inflammatory cytokines 
such as IL-22.
The Th17-iTreg Dichotomy
Involvement of TGF-β in the differentiation of both Th17 cells 
and iTreg cells suggests a special kinship between these two 
lineages of CD4+ T cells. However, the induction of the two 
lineages appears to be mutually exclusive: conditions favor-
ing Th17 cell differentiation (TGF-β and IL-6) inhibit iTreg cell 
generation, and conditions promoting iTreg cell production 
(TGF-β, IL-2, and retinoic acid) block Th17 cell differentiation. 
The molecular mechanisms underlying this reciprocal differ-
entiation of Th17 and iTreg cells remain incompletely under-
stood, though a recent study has uncovered some clues. The 
study found that although TGF-β induced the expression of 
both Foxp3 and RORγt in a subset of CD4+ T cells, RORγt 
induction of Th17 cell differentiation was inhibited by Foxp3 
though a mechanism partially mediated by physical interac-
tion between the two transcription factors (Zhou et al., 2008) 
(Figure 3).
Th17 cells, presumably of the regulatory form, are present 
constitutively in the mouse intestinal lamina propria (Ivanov 
et al., 2006). Gut-associated lymphoid tissue may also be 
a primary site for the generation of iTreg cells. Together, 
these observations suggest that TGF-β-induced Th17 cells 
and iTreg cells have important functions in the regulation of immune responses in the gut. TGF-β induction of Th17 cell 
and iTreg cell differentiation is reminiscent of TGF-β promo-
tion of B cell IgA antibody class switching (Li et al., 2006b). 
Because IgA is also critically involved in mucosal immune 
defense, it is tempting to speculate that the positive effects of 
TGF-β on T and B lymphocyte differentiation were selected for 
during evolution to fulfill the special requirements of mucosal 
immune homeostasis.
T Cell-Derived TGF-β1 Regulates T Cells
Among the three types of TGF-β molecules found in mam-
mals, TGF-β1 plays the most critical role in the regulation of 
T cell responses in vivo. TGF-β1 can be produced by multiple 
lineages of leukocytes and stromal cells and is secreted as a 
latent form in a complex with LAP and LTBP (Figure 1). TGF-β1 
cannot bind to its receptors in its latent form until it is liber-
ated from the constraints of LAP and LTBP binding. This com-
plex mode of TGF-β1 regulation presents many new questions, 
including those concerning the identity of the cellular sources 
of TGF-β1 and the mechanisms of TGF-β1 activation from its 
latent form.
T Cell-Derived TGF-β1 Control of T Cell Tolerance
An early attempt to study the cellular mechanisms by which 
TGF-β1 regulates T cells investigated whether endocrine 
TGF-β1 is sufficient to control T cells in vivo. Liver-specific 
expression of an active form of TGF-β1 restored TGF-β1 
levels in the blood of TGF-β1-deficient mice (Longenecker 
et al., 2002). However, this circulation of TGF-β1 at nor-
mal levels in the mutant mice still failed to ameliorate the 
lethal phenotype of TGF-β1 deficiency, thus suggesting 
that TGF-β1 control of T cell tolerance is mediated by both 
autocrine and paracrine sources of TGF-β1. A recent study 
investigating the function of T cell-produced TGF-β1 in vivo 
found that mice lacking the Tgfb1 gene specifically in T cells 
(Li et al., 2007) developed wasting colitis similarly to CD4-
DNRII mice that have attenuated TGF-β signaling in T cells, 
suggesting that T cell-produced TGF-β1 directly regulated 
T cells. Indeed, in the absence of T cell-produced TGF-β1, 
T cells underwent hyperproliferation, activation, and effec-
tor T cell differentiation. Studies of T cell-specific TGF-
βRII-deficient mice or TGF-β1-deficient mice have revealed 
that TGF-β1 is involved in the maintenance of peripheral 
Treg cells (Li et al., 2006a; Marie et al., 2005; Marie et al., 
2006). In addition, despite diminished Treg cell numbers 
in the spleen, TGF-βRII-deficient Treg cells underwent 
enhanced proliferation (Li et al., 2006a). These findings 
demonstrate that TGF-β plays a role in both the inhibition 
of Treg cell proliferation and the maintenance of Treg cells. 
Deletion of the Tgfb1 gene in T cells led to enhanced Treg 
cell proliferation and expansion in peripheral lymph nodes 
and the spleen (Li et al., 2007). These findings suggest that 
Treg cell maintenance is likely dependent on other cellular 
sources of TGF-β1. Interestingly, colonic Treg cells from 
these mice lacking TGF-β1 in T cells expressed reduced 
levels of Foxp3 as compared to the Treg cells from periph-
eral lymph nodes (Li et al., 2007). Because TGF-β, in syn-
ergy with retinoic acid, is likely involved in the induction 
of iTreg cells in gut-associated lymphoid tissue, it is con-Cell 134, August 8, 2008 ©2008 Elsevier Inc. 399
ceivable that T cell-produced TGF-β1 might be required for 
the optimal induction of Foxp3 expression and the de novo 
generation of iTreg cells in the colon.
In vitro stimulation of cultured T cells via their TCRs induced 
TGF-β1 production from both Treg cells and naive T cells (Li 
et al., 2007). To examine the function of TGF-β1 produced by 
these T cell subsets, Li et al. used a T cell transfer model of 
colitis in which the transfer of naive T cells to lymphopenic 
hosts induces colitis that is inhibited by the cotransfer of Treg 
cells. These transfer experiments showed that Treg-produced 
TGF-β1 was essential for the inhibition of colitis induced by 
naive T cells by blocking naive T cell differentiation into Th1 
cells (Li et al., 2007). These findings suggest that production 
of TGF-β1 is a critical mechanism used by Treg cells to control 
immune tolerance (Figure 4).
T Cell-Derived TGF-β1 Control of Th17 Cells
Local but not systemic administration of neutralizing TGF-β1 
antibody inhibited Th17 cell differentiation and the induc-
tion of EAE (Veldhoen et al., 2006b), suggesting that Th17 
cell differentiation is also mediated by autocrine and para-
crine sources of TGF-β1. Th17 cell number was diminished 
in T cell-specific TGF-β1-deficient mice both under steady-
state conditions and during EAE (Li et al., 2007). As a con-
sequence, these mice were almost completely resistant to 
the induction of EAE. These findings demonstrate an essen-
tial role for T cell-produced TGF-β1 in promoting Th17 cell 
differentiation in vivo. It remains to be determined whether 
TGF-β1 produced by Treg cells, non-Treg cells, or both 
are involved in Th17 cell differentiation. Notably, Treg cells 
enhanced the Th17 cell differentiation induced by LPS-stim-
ulated dendritic cells in vitro (Veldhoen et al., 2006a). In addi-
tion, in a model of systemic autoimmune disease, cotransfer 
of Treg cells with naive T cells inhibited IFN-γ expression 
but enhanced IL-17 production (Lohr et 
al., 2006). These observations suggest 
a proinflammatory function for Treg 
cells in the promotion of Th17 cell dif-
ferentiation through the production of 
TGF-β1. Should this be proven in ani-
mal models such as Treg cell-specific 
TGF-β1-deficient mice, it would have ramifications for the 
precautions that would need to be taken in attempts to use 
Treg cells for treating autoimmune diseases and transplant 
rejection.
Integrins Mediate TGF-β1 Activation
TGF-β1 activation proceeds through the LAP degradation or 
altered conformation that results in the release of the mature 
TGF-β1 homodimer. Putative activators of TGF-β1 in this pro-
cess include proteases such as plasmin and matrix metallo-
proteinases, reactive oxygen species, the protein thrombos-
pondin-1, and the integrins αvβ6 or αvβ8 (Annes et al., 2003). 
Activation of TGF-β1 in the latent complex by the integrins αvβ6 
and αvβ8 is dependent on their binding to an RGD (arginyl-gly-
cyl-aspartic acid) motif in LAP. Upon binding, the two integrins 
activate TGF-β1 though different mechanisms that may allow 
spatial regulation of TGF-β action. αvβ6-mediated activation 
occurs through a conformational change in LAP and not via 
the release of active TGF-β1 from the latent complex (Munger 
et al., 1999). As a consequence, presentation of αvβ6-activated 
TGF-β1 requires cell-to-cell contact. On the other hand, αvβ8-
induced TGF-β1 activation is dependent on metalloproteinase-
mediated degradation of LAP that results in the release of active 
TGF-β1 into the extracellular environment (Mu et al., 2002). This 
mode of activation ensures that TGF-β1 action occurs at some 
distance away from the site of TGF-β1 activation. Interestingly, 
mutation of a single residue in the integrin binding motif on LAP 
was sufficient to abolish the integrin-dependent activation of 
TGF-β1, though TGF-β1 processing and secretion remained 
normal. Mice homozygous for this Tgfb1 mutant allele devel-
oped a lethal immune phenotype indistinguishable from that of 
TGF-β1-deficient mice, thus revealing an indispensable role for 
integrins in the activation of TGF-β1 in vivo (Yang et al., 2007b).
Figure 4. A Three-Cell Model for TGF-β1-
Dependent Regulation of T Cells
Upon recognition of antigens presented by den-
dritic cells (DCs), Treg cells are activated and se-
crete the latent form of TGF-β1. This latent form 
comprises a TGF-β1 dimer associated with the 
latency-associated protein (LAP), which may addi-
tionally recruit latent TGF-β-binding protein (LTBP). 
Interaction of LAP with αvβ8 integrin expressed by 
DCs triggers degradation of LAP (mediated by un-
identified proteases, not shown) and the release 
of the active form of TGF-β1. Active TGF-β1 sub-
sequently acts on naive CD4+ T cells via a para-
crine mechanism to inhibit their differentiation into 
Th1 or Th2 cells and to promote their differentia-
tion into induced regulatory T (iTreg) cells, regula-
tory Th17 (rTh17) cells, or effector Th17 (eTh17) 
cells. Activated CD4+ T cells can also produce low 
amounts of latent TGF-β1 that potentially regulate 
T cell differentiation through an autocrine route.400 Cell 134, August 8, 2008 ©2008 Elsevier Inc.
Effects of αvβ6 and αvβ8 Integrin Loss
The αvβ6 integrin is expressed in a subset of epithelial cells. 
Mice deficient in αvβ6 showed a defect in Langerhans cell dif-
ferentiation (Yang et al., 2007b), a process recently found to 
require Langerhans cell-produced TGF-β1 (Kaplan et al., 2007). 
However, the inflammatory phenotype developed in αvβ6-
deficient mice is much milder than that of TGF-β1-deficient 
mice, suggesting that αvβ6 is not essential for the activation 
of TGF-β1 involved in the regulation of T cells. αvβ8 integrin is 
expressed in multiple immune cell types including T cells and 
the myeloid lineage dendritic cells. Interestingly, deletion of the 
gene encoding integrin β8 in dendritic cells, but not in T cells, 
in mice led to the development of colitis and a reduction in 
colonic Treg cells (Travis et al., 2007). In addition, compared to 
wild-type dendritic cells, β8-deficient dendritic cells produced 
lower levels of active TGF-β1 and were incapable of supporting 
iTreg cell differentiation in vitro. Similar colitis and T cell defects 
were also observed in mice with the ablation of αv integrins in 
the myeloid cell lineage (Lacy-Hulbert et al., 2007).
A Three-Cell Model of TGF-β1 Control of T Cells
The inflammatory and T cell phenotypes developed by the den-
dritic cell-specific β8-deficient mice are remarkably similar to 
those observed in mice with a T cell-specific deletion of the 
Tgfb1 gene (Li et al., 2007; Travis et al., 2007). On the basis of 
these findings, we propose a “three-cell” model for TGF-β1-
dependent regulation of T cell responses involving Treg cells, 
dendritic cells, and naive T cells (Figure 4). In this model, Treg 
cells produce latent TGF-β1 upon TCR stimulation by den-
dritic cell-presented antigens. This latent TGF-β1 is activated 
via dendritic cell αvβ8-dependent mechanisms to create an 
active TGF-β1 milieu around the dendritic cells that regulate 
the activation and differentiation of naive T cells. Active TGF-β1 
inhibits naive T cell differentiation into effector Th1 or Th2 cells 
and promotes their differentiation into iTreg or Th17 cells. The 
involvement of dendritic cells in the activation of Treg cell-
produced TGF-β1 is consistent with the finding that Treg cells 
formed long-lasting interactions with dendritic cells, which 
impaired the subsequent dendritic cell induction of effector T 
cell differentiation (Tang et al., 2006). Given that dendritic cells 
are likely the only antigen-presenting cells capable of priming 
naive T cells, the engagement of dendritic cells in TGF-β1 acti-
vation ensures the availability of active TGF-β1 at sites of naive 
T cell antigen recognition and subsequent T cell regulation by 
TGF-β1. On the other hand, the engagement of a different cell 
type (Treg cells) from dendritic cells as the source of TGF-β1 
warrants its conditional availability, which may be important for 
dendritic cells to induce potent Th1 and Th2 cell responses 
during infection, when Treg cell production of TGF-β1 might be 
inhibited. However, it is important to note that the inflamma-
tory and T cell phenotypes observed in T cell-specific TGF-β1-
deficient mice or dendritic cell-specific αvβ8 integrin-deficient 
mice are less severe than those of mice completely lacking 
TGF-β1 or mice expressing the mutant allele of Tgfb1 defec-
tive for integrin interaction. These observations suggest that 
TGF-β1 produced by cell types other than T cells and integrins 
other than dendritic cell-expressed αvβ8 are also involved in 
the regulation of T cells. The identities of these alternative cel-
lular sources of T cell regulation remain to be determined.Future Perspectives
By regulating thymic T cell development and peripheral T cell sur-
vival, proliferation, and differentiation, TGF-β ensures the main-
tenance of a diverse and self-tolerant T cell repertoire and the 
initiation of appropriate T cell responses essential for an effec-
tive adaptive immune system. The versatile functions of TGF-β 
in T cell control are likely due to the amendable nature of TGF-β 
signaling, which can be integrated with signals from various envi-
ronmental stimuli. The unique mechanism of extracellular TGF-β 
activation also creates a platform for TGF-β to integrate signals 
from multiple cell types to regulate T cells. The TGF-β pathway 
originated about one billion years ago (Newfeld et al., 1999), well 
before the inception of the lymphocyte-based adaptive immune 
system. The remarkably potent and pleiotropic functions of TGF-β 
in regulating T cell responses are reminiscent of its roles in more 
ancient biological processes such as embryonic development 
and carcinogenesis. It remains incompletely understood how the 
TGF-β system has been rewired at the molecular and cellular lev-
els to regulate T cells. Additional insights into the control of T cell 
responses by TGF-β will not only help to illuminate the fundamen-
tal principles of T cell regulation but also should facilitate the har-
nessing of TGF-β to treat a variety of immune-related disorders.
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